论文部分内容阅读
目的 :观察比卡鲁胺、戈舍瑞林持续内分泌治疗联合注射用白蛋白结合型紫杉醇、泼尼松在中晚期前列腺癌患者中的临床疗效。方法:将100例确诊为中晚期前列腺癌的患者随机分为对照组和观察组各50例。对照组患者采用比卡鲁胺片联合醋酸戈舍瑞林缓释植入剂治疗,观察组在对照组用药基础上加用注射用白蛋白结合型紫杉醇和泼尼松治疗。治疗3个周期后,比较2组患者的临床疗效和不良反应。结果:观察组患者的完全缓解率(22.0%)和部分缓解率(60%)高于对照组(8%和40%,P值均<0.05);观察组患者的中位生存期和中位无进展生存期(51个月和54个月)均长于对照组(33个月和30个月,P值均<0.05)。观察组患者的临床症状(疼痛、血清前列腺特异性抗原、前列腺体积和最大尿流率)明显改善。2组患者不良反应间的差异无统计学意义(P>0.05)。结论:内分泌药物联合注射用白蛋白结合型紫杉醇和泼尼松在中晚期前列腺癌患者中的疗效较好。
Objective: To observe the clinical efficacy of bicalutamide and goserelin for continuous endocrine therapy combined with albumin-bound paclitaxel and prednisone in patients with advanced prostate cancer. Methods: 100 patients diagnosed as advanced stage prostate cancer were randomly divided into control group and observation group of 50 cases. Patients in the control group were treated with bicalutamide tablets and goserelin acetate sustained release implants. The observation group was treated with albumin-bound paclitaxel and prednisone in addition to the control group. After 3 cycles of treatment, the clinical efficacy and adverse reactions in 2 groups were compared. Results: The complete remission rate (22.0%) and partial remission rate (60%) in the observation group were significantly higher than those in the control group (8% vs 40%, P <0.05). The median survival and median Progression-free survival (51 months and 54 months) was longer in the control group (P <0.05) at 33 and 30 months. Clinical symptoms (pain, serum prostate-specific antigen, prostate volume, and maximum flow rate) in the observation group were significantly improved. There was no significant difference in adverse reactions between the two groups (P> 0.05). Conclusion: The combination of endocrine drugs with albumin-bound paclitaxel and prednisone in patients with advanced prostate cancer is better.